BERLIN--(BUSINESS WIRE)-- Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III ...

Bayer AG’s BAYRY wholly owned, independently operated subsidiary BlueRock Therapeutics LP announced positive 36-month data from an early-stage study of bemdaneprocel, an investigational cell therapy ...

Berlin, Germany – June 17th, 2025 – Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected ...

Collaboration focuses on developing potential best in class siRNA-based treatment for a form of dilated cardiomyopathy Bayer to further strengthen cardiovascular portfolio and enter dynamic field of ...